Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma

Inclusion Criteria: * appropriately signed and dated ICON prior to study specific action * IgE-mediated Sensitization against grass pollen * Perception of disease activity of at least 30 mm on a 100 mm VAS * FEV1 or a PEFR value \> 80% of predicted normal value * Allergic rhinitis and/or rhinoconjunctivitis symptoms (at least 2 years) with or without intermittent asthma symptoms verified by: * suggestive medical history AND * specific IgE against grass pollen with CAP-RAST ≥ 2 AND * a positive SPT (wheal diameter ≥ 3 mm) AND * a positive CPT for grass pollen * Patients with co-allergies are allowed to enter the study: * being asymptomatic against co-allergens such as tree or weed pollen, house dust mites, cat and dog, and other country specific allergens * with CAP-RAST co-allergen \< grass (detailed specifications given for Birch, HDM, animal dander, other country specific allergens) * All other co-allergens: difference in CAP RAST co-allergen to grass of ≥ 2 and an SPT wheal diameter co-allergen \< grass * Females of non-childbearing potential must be postmenopausal for at least 1 year or surgically sterilized * Females of childbearing potential must be non-lactating, non-pregnant and must correctly use an effective method of contraception during the study. Exclusion Criteria: * Acute or chronic infectious conjunctivitis * History of significant clinical manifestations of allergy as a result of sensitisation against trees or weed pollen and perennial allergens (e.g., house dust mites) Patients are not allowed to enter into the study: * with typical symptoms against co-allergens such as tree or weed pollen, HDM, cat and dog, and other country specific allergens * with CAP-RAST co-allergen ≥ grass * Persistent asthma, according to Global Initiative for Asthma (GINA) * Acute or chronic inflammatory or infectious airways disease * Chronic structural disease of the lung (e.g., emphysema or bronchiectasis) * Autoimmune and/or immune deficiency * Any disease that prohibits the use of adrenaline (e.g., hyperthyroidism) * Severe uncontrolled disease that could increase the risk to the patients while participating in the study, including but not limited to: cardiovascular insufficiency, severe or unstable lung diseases, endocrine diseases, clinically significant renal or hepatic diseases or haematological disorders. * Active malignant disease during the previous 5 years * Significant abnormal laboratory parameter or alteration in vital signs that could increase the risk to the study patient * Abuse of alcohol, drugs or medications within the past year * Severe psychiatric, psychological or neurological disorder * Immunotherapy against grass pollen within the last 5 years * Systemic and/or topical treatment with β-blockers within 1 wk prior to V2 * Use of medication that may interfere with the immune system or has been using any medication which might still have an influence on the immune system at V2 * Use of tranquiliser or psychoactive drugs within 1 week prior to V1 * Use of systemic corticosteroids within 3 months prior to V1 * Immunization with vaccines within 7 days prior to V2 * Expected non-compliance and/or no cooperation * Participation in another clinical study within 30 days prior to V2 * Prior participation in this study * Employees at the investigational centre or first degree relative or partner of the investigator * Planed donation of germ cells, blood, organs or bone marrow during the course of the study * Contractually not capable * A positive pregnancy test at V1 * Jurisdictional or governmentally institutionalised.